Trials / Completed
CompletedNCT02216409
Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody
A First-in-Human Phase 1 Dose Escalation Trial of Hu5F9-G4 in Patients With Advanced Solid Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 88 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability of Hu5F9-G4 in participants with solid tumors.
Detailed description
This is a first-in-human, first-in-class, escalating dose trial of an antibody that inhibits an anti-apoptotic signal in human macrophages. The major aims of the study are to define the safety profile of this new drug, and to determine a recommended dose and schedule for potential additional trials.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hu5F9-G4 |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2018-10-01
- Completion
- 2018-12-01
- First posted
- 2014-08-15
- Last updated
- 2019-02-05
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02216409. Inclusion in this directory is not an endorsement.